Navigation Links
Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis
Date:3/14/2012

t, Dubai Hospital.

"We are excited to be able to prescribe Omnaris® to our patients in UAE as a new treatment option as approved by the authorities" said Dr. Hussain.

Omnaris® Nasal Spray provides a fast-acting and long-lasting, well tolerated and effective therapy for allergy sufferers in the UAE. Nycomed, a Takeda company, plans to launch Omnaris® in other countries in the Middle Eastern region in 2012 and providing a novel treatment option for patients.

The introduction of Omnaris® into the Middle Eastern market coincides with the release of the intriguing Allergies in Middle East (AIME) Survey sponsored by Nycomed, a Takeda Company, a global pharmaceutical company. The AIME Survey screened 7,411 households in Egypt, Iran, Lebanon, Saudi Arabia and UAE. In total 501 adults and parents of children and adolescents with allergic rhinitis were surveyed. The results show that nasal allergies diminish quality of life by preventing participation in outdoor activities, interfere in work and academic performance, and overall leave allergy sufferers of all ages feeling tired, depressed or sad and miserable as a result of bothersome symptoms. Notably, most seek relief with medication, but approximately half of adults and children reported that their current nasal allergy spray failed to provide 24-hour relief and it was not effective enough to treat all symptoms.  

Notes to editors:

The following backgrounders are available upon request:

  • Allergic Rhinitis Backgrounder
  • Allergies in the Middle East Survey Backgrounder

The Allergies in the Middle East Survey is the latest in a series of allergy surveys supported by Nycomed, a Takeda Company in five regions around the world. For more information on Allergies in the Middle East Survey, please visit http://www.allergiesin
'/>"/>

SOURCE Takeda
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
2. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
3. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
4. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
5. Poplar Healthcare Forms Parent Company, Launches New Web Site
6. CorCell, a Cord Blood America Company, Launches Referral Rewards Program
7. BioCells, Inc., a Cord Blood America Company, to Begin Storing Dental Pulp Stem Cells in Argentina
8. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
9. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
10. Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 Swine Flu Virus Outbreak
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
(Date:12/13/2014)... - MaRS and Virgin Unite Canada, the non-profit foundation of ... to support Canadian entrepreneurs tackling social and environmental challenges. Today, ... the MaRS Centre to announce the new partnership, which includes ... fund has $1 million in seed capital provided by Virgin ... Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... Draws Participants From A Broad Range of Industries Despite ... edition of InformexUSA officially opened its exhibition floors Wednesday ... show traffic in 2008. The week long exhibition & ... in North America, is featuring an expanded program to ...
... Mass., Jan. 29 Repligen Corporation (Nasdaq: ... Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... 2009 at 10:00 a.m. EST, to report third quarter ... quarterly update of the Company.This call is being webcast ...
... 29, 2009 Senomyx, Inc. (Nasdaq: SNMX ) ... fiscal year ending December 31, 2008 on Thursday, February 12, ... The Company will also host a conference call and live ... Time) that same day. During the call, Senomyx,s management ...
Cached Biology Technology:InformexUSA 2009 Opens to Strong Attendance 2InformexUSA 2009 Opens to Strong Attendance 3InformexUSA 2009 Opens to Strong Attendance 4Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 3SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... rich in omega-3 fatty acids can inhibit growth of breast ... from the University of Guelph. The study, published recently ... to be the first to provide unequivocal evidence that omega-3s ... Ma, a professor in Guelph,s Department of Human Health and ...
... Washington, DC The Entomological Society of America (ESA) ... today a new partnership that will provide ESA members ... policy debates. The ESA is the ... scientific needs of entomologists and individuals in related disciplines. ...
... of Southampton have identified the molecular system that ... brain during neurodegenerative diseases. An important aspect ... Huntington,s or prion disease, is the generation of ... Results from the study open new avenues ...
Cached Biology News:Omega-3s inhibit breast cancer tumor growth, study finds 2Entomological Society of America launches science policy program 2Scientists identify molecular system that could help develop treatments for Alzheimer's disease 2